Corneal Toxicity in Patients Treated by Belantamab Mafodotin

Status Completed

Clinical Trial Summary

Belantamab Mafodotin is the first antibody conjugate targeting B-cell maturation antigen (BCMA) in relapsed or refractory multiple myeloma (RRMM). It is used in multiple myeloma refractory to an immunomodulatory drug or proteasome inhibitor and refractory and/or intolerant to an anti-CD38 monoclonal antibody. It has been found that the immunotherapy causes corneal side effects, Microcyst-like Epithelial Changes (MECs). They are round-shaped corneal inclusions that migrate from the peripheral cornea to the center, causing blurry vision, dryness and refractive shifts depending on their location and density.

Clinical Trial Description

This study aims at analysing the refractive shifts caused by Microcyst-like Epithelial Changes (MECs) and whether it can be used to monitor patients and facilitate their follow up. Constitution of a French multicenter cohort. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05887206
Study type	Observational
Source	Centre Hospitalier Universitaire de Saint Etienne
Contact
Status	Completed
Phase
Start date	May 2, 2022
Completion date	May 2, 2023

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT06205823` - Compare Clinical Outcomes Between Advanced Immunotherapy and Classical Immunochemotherapy in RRMM
Recruiting	`NCT04782687` - Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma	Phase 2
Active, not recruiting	`NCT05889221` - Multicenter Phase 2 Study of Subcutaneous Isatuximab Plus Bortezomib, Lenalidomide and Dexamethasone in the Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma	N/A
Recruiting	`NCT03891914` - Prospective Comparison of 18F-choline PET/CT and 18F-FDG PET/CT in the Initial Work-up of Multiple Myeloma	Phase 3
Not yet recruiting	`NCT05944783` - Bioequivalence Studies of Dasatinib 100 mg	Phase 4
Recruiting	`NCT04268199` - A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment	Phase 2
Not yet recruiting	`NCT06133426` - Evaluation of the Role of Connected Scales in the Therapeutic Care of Hematology Patients	N/A
Completed	`NCT04065789` - Carfilzomib in Combination With Daratumumab, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM Patients	Phase 2
Active, not recruiting	`NCT03089411` - Collection of Additional Data Followed the Study IFM 2013-04	N/A
Completed	`NCT04436029` - Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy	Phase 2
Not yet recruiting	`NCT04364724` - CTFEA Myeloma Study
Recruiting	`NCT05932680` - Limited-duration Teclistamab	Phase 2
Not yet recruiting	`NCT06418750` - Evaluation of a Range of Dermo-cosmetic Products to Treat Skin and Nail Toxicity Linked to Bispecific Anti-GPRC5D Bispecific Antibodies in Multiple Myeloma Patients". Myeloma". Descriptive Pilot Study	N/A
Completed	`NCT04236063` - Rehabilitation Needs of the Malaysian Haematological Cancer Survivors
Terminated	`NCT04242121` - The Risk Stratification in Patients With Multiple Myeloma Based on Fluorescence Flow Cytometry Quantitative Determination of the Circulating Plasma Cells in the Peripheral Blood
Not yet recruiting	`NCT03607643` - A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies	Phase 1/Phase 2
Recruiting	`NCT05651932` - A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma	Phase 1
Not yet recruiting	`NCT06245629` - Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma
Recruiting	`NCT03992170` - Study of Daratumumab in Multiple Myeloma (MM) Patients in >VGPR/MRD-positive	Phase 2
Terminated	`NCT04843579` - Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients	Phase 2